Provided by Tiger Trade Technology Pte. Ltd.

Esperion Therapeutics

3.30
-0.0400-1.20%
Post-market: 3.300.00000.00%16:02 EST
Volume:2.73M
Turnover:9.08M
Market Cap:788.91M
PE:-6.16
High:3.39
Open:3.36
Low:3.28
Close:3.34
52wk High:4.18
52wk Low:0.6925
Shares:239.06M
Float Shares:237.00M
Volume Ratio:0.98
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5358
EPS(LYR):-0.2764
ROE:97.76%
ROA:-5.42%
PB:-1.75
PE(LYR):-11.94

Loading ...

Esperion Therapeutics Inc -Commercial Launch for Nilemdo Is Expected in Q2 2026

THOMSON REUTERS
·
Nov 18, 2025

HLS Therapeutics Inc - Commercial Launch Expected in Q2 2026

THOMSON REUTERS
·
Nov 18, 2025

Esperion Therapeutics Files Initial Beneficial Ownership Statement for Chief Commercial Officer John B. Harlow Jr

Reuters
·
Nov 18, 2025

Stock Track | Esperion Therapeutics Soars 5.26% as New Data Shows NEXLETOL Reduces Cardiovascular Events and Blood Clots

Stock Track
·
Nov 10, 2025

Esperion Reports Bempedoic Acid Cuts Major Cardiovascular Events and Venous Thromboembolism in CLEAR Outcomes Study

Reuters
·
Nov 10, 2025

Esperion Announces New Data From Clear Outcomes Highlighting Value of Nexletol® (Bempedoic Acid) in Oral and Poster Presentations at the Aha Scientific Sessions 2025

THOMSON REUTERS
·
Nov 10, 2025

Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025

GlobeNewswire
·
Nov 10, 2025

Esperion Therapeutics Grants 77,650 RSUs to New Employees Under Inducement Plan

Reuters
·
Nov 07, 2025

Esperion Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Nov 07, 2025

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Nov 07, 2025

Esperion Q3 revenue up 69% on prescription volumes

Reuters
·
Nov 06, 2025

Stock Track | Esperion Therapeutics Plunges 6.12% Pre-market on Disappointing Q3 Earnings

Stock Track
·
Nov 06, 2025

Stock Track | Esperion Therapeutics Plunges 6.12% Pre-Market on Disappointing Q3 Earnings

Stock Track
·
Nov 06, 2025

Esperion Therapeutics Q3 EPS $(0.16) Misses $(0.08) Estimate, Sales $87.309M Beat $77.803M Estimate

Benzinga
·
Nov 06, 2025

Esperion Reiterates 2025 Operating Expense Guidance at $215–$235 Million

Reuters
·
Nov 06, 2025

BRIEF-Esperion Therapeutics Q3 Product Sales USD 40.659 Million

Reuters
·
Nov 06, 2025

Esperion Therapeutics Inc Reiterates Its Expectation for Full Year 2025 Operating Expenses to Be in the Range of $215 Million to $235 Million

THOMSON REUTERS
·
Nov 06, 2025

Esperion Therapeutics Expects to Achieve Sustainable Profitability Beginning in the First Quarter of 2026

THOMSON REUTERS
·
Nov 06, 2025

Esperion Therapeutics Appoints John Harlow as Chief Commercial Officer

Reuters
·
Nov 04, 2025

Press Release: Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

Dow Jones
·
Nov 04, 2025